Drugs / ERAS-007
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04959981 | Sep 2021 → Apr 2023 | non-small cell lung carcinoma | Erasca, Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05279859 | Mar 2022 → Mar 2025 | acute myeloid leukemia | Erasca, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05039177 | Sep 2021 → Aug 2025 | colorectal cancer, pancreatic ductal adenocarcinoma | Erasca, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04866134 | May 2021 → Nov 2026 expected | — | Erasca, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERAS-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05039177 ↗ |
| Action | Inhibit | “ERK Inhibitor” NCT04866134 ↗ |
| Route | Oral | “ERAS-007 will be administered orally” NCT04866134 ↗ |